UAE National Media Office announces a non-profit to drive innovation, sustainability, and authenticity in media
WASHINGTON, March 12, 2025 /PRNewswire/ -- In a bold move to redefine the future of global media, the UAE National Media Office today unveiled BRIDGE, a groundbreaking initiative designed to create a dynamic and inclusive ecosystem that empowers media professionals, fosters innovation, and champions responsible journalism in the digital age. The initiative will be powered by a non-profit vehicle, the BRIDGE Foundation.
The initiative was launched by His Excellency Abdullah bin Mohammed bin Butti Al Hamed, Chairman of the UAE National Media Office, alongside His Excellency Dr. Jamal Mohammed Obaid Al Kaabi, Director-General of the UAE National Media Office, and Richard Attias, Founder & Chairman, Richard Attias & Associates. The event brought together a powerhouse of journalists, publishers, innovators, investors, policymakers, and thought leaders from around the world, united by a common goal: to shape the future of media through collaboration, innovation, and strategic action.
"Media is the pulse of a thriving society. It informs and inspires us, it shapes global perceptions and influences international dialogues, and it connects cultures from around the world," said H.E. Abdullah bin Mohammed bin Butti Al Hamed. "By convening the brightest minds from across the global media landscape, this initiative will empower the next generation of storytellers, invest in ethical AI, champion press freedoms, and ensure that authenticity and integrity remain at the core of our industry."
As the media grapples with AI-driven disruptions, shifting audience behaviors, and evolving business models, BRIDGE seeks to provide a global forum for thought leadership, investment, and technological advancement. The initiative will serve as a catalyst for future-focused media strategies, equipping industry professionals with the tools, networks, and insights needed to thrive in an era of digital transformation.
"This platform is built on the belief that partnerships, not silos, will define the future — particularly when it comes to media. The media is not just a witness to history; it is a force that shapes it," said Richard Attias.
BRIDGE functions as a year-round platform for engagement, collaboration, and action, culminating with the world's largest and most influential gathering of media in Abu Dhabi on December 8-10, 2025.
"BRIDGE is designed to tackle the most pressing challenges of our industry and deliver real-world solutions. It is not just about dialogue—it is about economic opportunity," said H.E. Dr. Jamal Mohammed Obaid Al Kaabi. "At our flagship December conference, the BRIDGE Showcase and Marketplace will be a launchpad for startups, a deal-making hub for investors, and a catalyst for business collaboration."
BRIDGE will build upon the UAE's position as a leader in innovation, investment, and AI policy. Further details on the initiative's strategic partnerships, objectives, and roadmap will be revealed in Abu Dhabi this December.
For more information, visit The United Arab Emirates National Media Office.
Contact : Maryam bin Fahad | mfahad@nmo.gov.ae
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
UAE Launches BRIDGE: A Global Initiative to Transform the Media Landscape
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
